Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety

BACKGROUND/AIMS: The treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection. We investigated the real-world efficacy, changes in liver stiffness and noninvasive fibrosis markers, and the safety...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Gut Liver
Главные авторы: Lee, Hye Won, Oh, Se Rim, Kim, Dong Yun, Jeong, Yechan, Kim, Seungtaek, Kim, Beom Kyung, Kim, Seung Up, Kim, Do Young, Ahn, Sang Hoon, Han, Kwang-Hyub, Park, Jun Yong
Формат: Artigo
Язык:Inglês
Опубликовано: Editorial Office of Gut and Liver 2018
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5945264/
https://ncbi.nlm.nih.gov/pubmed/29409309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5009/gnl17298
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы